Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study

In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7, PCV10, PCV13 and a mixed PCV10/PCV13 schedule were sequentially used without catch-up. The effectiveness of vaccination schedules to prevent serotype 19A invasive...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2024-12, Vol.42 (26), p.126379, Article 126379
Main Authors: Deceuninck, Geneviève, Brousseau, Nicholas, Lefebvre, Brigitte, Quach, Caroline, Tapiero, Bruce, Bui, Yen-Giang, Desjardins, Michael, De Wals, Philippe
Format: Article
Language:English
Subjects:
Age
Antigens
Child, Preschool
Children
Conjugates
Effectiveness
Female
Humans
Immunization
Immunization Programs
Immunization Schedule
Infant
Invasive pneumococcal disease
Laboratories
Male
Pneumococcal conjugated vaccine
Pneumococcal Infections - epidemiology
Pneumococcal Infections - immunology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - immunology
Public health
Quebec
Quebec - epidemiology
Schedules
Serogroup
Serotype-19A
Streptococcus pneumoniae
Streptococcus pneumoniae - classification
Streptococcus pneumoniae - immunology
Transplants & implants
vaccination
Vaccination - methods
Vaccine effectiveness
Vaccine Efficacy
Vaccines
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c304t-4fc11548e16f919cc422939be3756f0b0f245eb697606cf899e0088679208a7d3
container_end_page
container_issue 26
container_start_page 126379
container_title Vaccine
container_volume 42
creator Deceuninck, Geneviève
Brousseau, Nicholas
Lefebvre, Brigitte
Quach, Caroline
Tapiero, Bruce
Bui, Yen-Giang
Desjardins, Michael
De Wals, Philippe
description In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7, PCV10, PCV13 and a mixed PCV10/PCV13 schedule were sequentially used without catch-up. The effectiveness of vaccination schedules to prevent serotype 19A invasive pneumococcal disease (IPD) in
doi_str_mv 10.1016/j.vaccine.2024.126379
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153855863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X24010612</els_id><sourcerecordid>3153855863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c304t-4fc11548e16f919cc422939be3756f0b0f245eb697606cf899e0088679208a7d3</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoso7rj6E5SANyvYmo9-JFcyDKsuLIqi4F1I01M3dZp0k7Qy_kZ_lBk6CnqjV8khz_uek-TNsscEFwST-sVQLEprY6GgmJYFoTVrxJ1sQ3jDcloRfjfbYFqXeUnw57PsQQgDxrhiRNzPzphgjFLWbLIfl30POpoFLISAXI_iDaAINkfKdqkwPkKqFrUHG9FkYR6ddlqrPdLODvMXFQGdRgkoOjR5WI5oAO_iYQJExBYZu6iQmvxp0JkAKkA6Re9naEE_RztlVacKtF13RllkxnG25ruKxlnkIUm8vkEW4jfnv6KL3dWHt89QiHN3eJjd69U-wKPTep59enX5cfcmv373-mq3vc41w2XMy14TUpUcSN0LIrQuKRVMtMCaqu5xi3taVtDWoqlxrXsuBGDMed0IirlqOnaeXay-k3e3M4QoRxM07PfKgpuDZKRivKp4zf4DJbihXHCc0Kd_oYObvU0XSVQasaK4FImqVkp7F4KHXk7ejMofJMHymAw5yNN3yGMy5JqMpHtycp_bEbrfql9RSMDLFYD0cosBL4M2YDV0xqeEyM6Zf7T4CbtdzeY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3142252049</pqid></control><display><type>article</type><title>Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study</title><source>ScienceDirect Journals</source><creator>Deceuninck, Geneviève ; Brousseau, Nicholas ; Lefebvre, Brigitte ; Quach, Caroline ; Tapiero, Bruce ; Bui, Yen-Giang ; Desjardins, Michael ; De Wals, Philippe</creator><creatorcontrib>Deceuninck, Geneviève ; Brousseau, Nicholas ; Lefebvre, Brigitte ; Quach, Caroline ; Tapiero, Bruce ; Bui, Yen-Giang ; Desjardins, Michael ; De Wals, Philippe</creatorcontrib><description>In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7, PCV10, PCV13 and a mixed PCV10/PCV13 schedule were sequentially used without catch-up. The effectiveness of vaccination schedules to prevent serotype 19A invasive pneumococcal disease (IPD) in &lt;5-year-old children was estimated by the indirect cohort method during 2009–2023. A total of 248 19A IPD cases and 457 IPD controls were included in the analysis. Adjusted vaccine effectiveness (VEa) for ≥1 dose was 57 % [95 %CI: −1 %,82 %] for PCV10 and 62 % [16 %,83 %] for PCV13. VEa for 3 doses was 69 % [17 %,88 %] for PCV10, 76 % [39 %,90 %] for PCV13 and 86 % [64 %,95 %] for the 2PCV10 + 1PCV13 schedule. Protection provided by the PCV10-only schedule tended to be of lower magnitude compared to the two other schedules. The mixed PCV10 + PCV13 schedule showed a protection against 19A IPD at least comparable to that of 3 PCV-13 doses.</description><identifier>ISSN: 0264-410X</identifier><identifier>ISSN: 1873-2518</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2024.126379</identifier><identifier>PMID: 39332237</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Antigens ; Child, Preschool ; Children ; Conjugates ; Effectiveness ; Female ; Humans ; Immunization ; Immunization Programs ; Immunization Schedule ; Infant ; Invasive pneumococcal disease ; Laboratories ; Male ; Pneumococcal conjugated vaccine ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - immunology ; Pneumococcal Infections - prevention &amp; control ; Pneumococcal Vaccines - administration &amp; dosage ; Pneumococcal Vaccines - immunology ; Public health ; Quebec ; Quebec - epidemiology ; Schedules ; Serogroup ; Serotype-19A ; Streptococcus pneumoniae ; Streptococcus pneumoniae - classification ; Streptococcus pneumoniae - immunology ; Transplants &amp; implants ; vaccination ; Vaccination - methods ; Vaccine effectiveness ; Vaccine Efficacy ; Vaccines ; Vaccines, Conjugate - administration &amp; dosage ; Vaccines, Conjugate - immunology</subject><ispartof>Vaccine, 2024-12, Vol.42 (26), p.126379, Article 126379</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2024. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c304t-4fc11548e16f919cc422939be3756f0b0f245eb697606cf899e0088679208a7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39332237$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deceuninck, Geneviève</creatorcontrib><creatorcontrib>Brousseau, Nicholas</creatorcontrib><creatorcontrib>Lefebvre, Brigitte</creatorcontrib><creatorcontrib>Quach, Caroline</creatorcontrib><creatorcontrib>Tapiero, Bruce</creatorcontrib><creatorcontrib>Bui, Yen-Giang</creatorcontrib><creatorcontrib>Desjardins, Michael</creatorcontrib><creatorcontrib>De Wals, Philippe</creatorcontrib><title>Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7, PCV10, PCV13 and a mixed PCV10/PCV13 schedule were sequentially used without catch-up. The effectiveness of vaccination schedules to prevent serotype 19A invasive pneumococcal disease (IPD) in &lt;5-year-old children was estimated by the indirect cohort method during 2009–2023. A total of 248 19A IPD cases and 457 IPD controls were included in the analysis. Adjusted vaccine effectiveness (VEa) for ≥1 dose was 57 % [95 %CI: −1 %,82 %] for PCV10 and 62 % [16 %,83 %] for PCV13. VEa for 3 doses was 69 % [17 %,88 %] for PCV10, 76 % [39 %,90 %] for PCV13 and 86 % [64 %,95 %] for the 2PCV10 + 1PCV13 schedule. Protection provided by the PCV10-only schedule tended to be of lower magnitude compared to the two other schedules. The mixed PCV10 + PCV13 schedule showed a protection against 19A IPD at least comparable to that of 3 PCV-13 doses.</description><subject>Age</subject><subject>Antigens</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Conjugates</subject><subject>Effectiveness</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs</subject><subject>Immunization Schedule</subject><subject>Infant</subject><subject>Invasive pneumococcal disease</subject><subject>Laboratories</subject><subject>Male</subject><subject>Pneumococcal conjugated vaccine</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - immunology</subject><subject>Pneumococcal Infections - prevention &amp; control</subject><subject>Pneumococcal Vaccines - administration &amp; dosage</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>Public health</subject><subject>Quebec</subject><subject>Quebec - epidemiology</subject><subject>Schedules</subject><subject>Serogroup</subject><subject>Serotype-19A</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pneumoniae - classification</subject><subject>Streptococcus pneumoniae - immunology</subject><subject>Transplants &amp; implants</subject><subject>vaccination</subject><subject>Vaccination - methods</subject><subject>Vaccine effectiveness</subject><subject>Vaccine Efficacy</subject><subject>Vaccines</subject><subject>Vaccines, Conjugate - administration &amp; dosage</subject><subject>Vaccines, Conjugate - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkl2L1DAUhoso7rj6E5SANyvYmo9-JFcyDKsuLIqi4F1I01M3dZp0k7Qy_kZ_lBk6CnqjV8khz_uek-TNsscEFwST-sVQLEprY6GgmJYFoTVrxJ1sQ3jDcloRfjfbYFqXeUnw57PsQQgDxrhiRNzPzphgjFLWbLIfl30POpoFLISAXI_iDaAINkfKdqkwPkKqFrUHG9FkYR6ddlqrPdLODvMXFQGdRgkoOjR5WI5oAO_iYQJExBYZu6iQmvxp0JkAKkA6Re9naEE_RztlVacKtF13RllkxnG25ruKxlnkIUm8vkEW4jfnv6KL3dWHt89QiHN3eJjd69U-wKPTep59enX5cfcmv373-mq3vc41w2XMy14TUpUcSN0LIrQuKRVMtMCaqu5xi3taVtDWoqlxrXsuBGDMed0IirlqOnaeXay-k3e3M4QoRxM07PfKgpuDZKRivKp4zf4DJbihXHCc0Kd_oYObvU0XSVQasaK4FImqVkp7F4KHXk7ejMofJMHymAw5yNN3yGMy5JqMpHtycp_bEbrfql9RSMDLFYD0cosBL4M2YDV0xqeEyM6Zf7T4CbtdzeY</recordid><startdate>20241202</startdate><enddate>20241202</enddate><creator>Deceuninck, Geneviève</creator><creator>Brousseau, Nicholas</creator><creator>Lefebvre, Brigitte</creator><creator>Quach, Caroline</creator><creator>Tapiero, Bruce</creator><creator>Bui, Yen-Giang</creator><creator>Desjardins, Michael</creator><creator>De Wals, Philippe</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>20241202</creationdate><title>Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study</title><author>Deceuninck, Geneviève ; Brousseau, Nicholas ; Lefebvre, Brigitte ; Quach, Caroline ; Tapiero, Bruce ; Bui, Yen-Giang ; Desjardins, Michael ; De Wals, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c304t-4fc11548e16f919cc422939be3756f0b0f245eb697606cf899e0088679208a7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Antigens</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Conjugates</topic><topic>Effectiveness</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs</topic><topic>Immunization Schedule</topic><topic>Infant</topic><topic>Invasive pneumococcal disease</topic><topic>Laboratories</topic><topic>Male</topic><topic>Pneumococcal conjugated vaccine</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - immunology</topic><topic>Pneumococcal Infections - prevention &amp; control</topic><topic>Pneumococcal Vaccines - administration &amp; dosage</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>Public health</topic><topic>Quebec</topic><topic>Quebec - epidemiology</topic><topic>Schedules</topic><topic>Serogroup</topic><topic>Serotype-19A</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pneumoniae - classification</topic><topic>Streptococcus pneumoniae - immunology</topic><topic>Transplants &amp; implants</topic><topic>vaccination</topic><topic>Vaccination - methods</topic><topic>Vaccine effectiveness</topic><topic>Vaccine Efficacy</topic><topic>Vaccines</topic><topic>Vaccines, Conjugate - administration &amp; dosage</topic><topic>Vaccines, Conjugate - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deceuninck, Geneviève</creatorcontrib><creatorcontrib>Brousseau, Nicholas</creatorcontrib><creatorcontrib>Lefebvre, Brigitte</creatorcontrib><creatorcontrib>Quach, Caroline</creatorcontrib><creatorcontrib>Tapiero, Bruce</creatorcontrib><creatorcontrib>Bui, Yen-Giang</creatorcontrib><creatorcontrib>Desjardins, Michael</creatorcontrib><creatorcontrib>De Wals, Philippe</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deceuninck, Geneviève</au><au>Brousseau, Nicholas</au><au>Lefebvre, Brigitte</au><au>Quach, Caroline</au><au>Tapiero, Bruce</au><au>Bui, Yen-Giang</au><au>Desjardins, Michael</au><au>De Wals, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2024-12-02</date><risdate>2024</risdate><volume>42</volume><issue>26</issue><spage>126379</spage><pages>126379-</pages><artnum>126379</artnum><issn>0264-410X</issn><issn>1873-2518</issn><eissn>1873-2518</eissn><abstract>In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7, PCV10, PCV13 and a mixed PCV10/PCV13 schedule were sequentially used without catch-up. The effectiveness of vaccination schedules to prevent serotype 19A invasive pneumococcal disease (IPD) in &lt;5-year-old children was estimated by the indirect cohort method during 2009–2023. A total of 248 19A IPD cases and 457 IPD controls were included in the analysis. Adjusted vaccine effectiveness (VEa) for ≥1 dose was 57 % [95 %CI: −1 %,82 %] for PCV10 and 62 % [16 %,83 %] for PCV13. VEa for 3 doses was 69 % [17 %,88 %] for PCV10, 76 % [39 %,90 %] for PCV13 and 86 % [64 %,95 %] for the 2PCV10 + 1PCV13 schedule. Protection provided by the PCV10-only schedule tended to be of lower magnitude compared to the two other schedules. The mixed PCV10 + PCV13 schedule showed a protection against 19A IPD at least comparable to that of 3 PCV-13 doses.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>39332237</pmid><doi>10.1016/j.vaccine.2024.126379</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2024-12, Vol.42 (26), p.126379, Article 126379
issn 0264-410X
1873-2518
1873-2518
language eng
recordid cdi_proquest_miscellaneous_3153855863
source ScienceDirect Journals
subjects Age
Antigens
Child, Preschool
Children
Conjugates
Effectiveness
Female
Humans
Immunization
Immunization Programs
Immunization Schedule
Infant
Invasive pneumococcal disease
Laboratories
Male
Pneumococcal conjugated vaccine
Pneumococcal Infections - epidemiology
Pneumococcal Infections - immunology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - immunology
Public health
Quebec
Quebec - epidemiology
Schedules
Serogroup
Serotype-19A
Streptococcus pneumoniae
Streptococcus pneumoniae - classification
Streptococcus pneumoniae - immunology
Transplants & implants
vaccination
Vaccination - methods
Vaccine effectiveness
Vaccine Efficacy
Vaccines
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - immunology
title Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A50%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20the%20ten-%20and%20thirteen-valent%20pneumococcal%20conjugate%20vaccines%20to%20prevent%20serotype%2019A%20invasive%20pneumococcal%20disease%20in%20Quebec,%20Canada.%20A%20Canadian%20immunization%20research%20network%20(CIRN)%20study&rft.jtitle=Vaccine&rft.au=Deceuninck,%20Genevi%C3%A8ve&rft.date=2024-12-02&rft.volume=42&rft.issue=26&rft.spage=126379&rft.pages=126379-&rft.artnum=126379&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2024.126379&rft_dat=%3Cproquest_cross%3E3153855863%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c304t-4fc11548e16f919cc422939be3756f0b0f245eb697606cf899e0088679208a7d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3142252049&rft_id=info:pmid/39332237&rfr_iscdi=true